FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approved Cosentyx® (secukinumab) for treating moderate to severe hidradenitis suppurativa (HS) in adults, based on Phase III trials showing symptom relief as early as Week 2. Cosentyx, the only IL-17A inhibitor for HS, demonstrated significant reductions in inflammatory nodules and abscesses, offering a new treatment option for this chronic, painful disease affecting 1 in 100 people globally.